E-LIB Suche - Ergebnisse für: Marquez-Rodas, I.

1

Nomogram for predicting survival after first-line anti-PD-1..:

Chatziioannou, E. ; Higuita, L.M. Serna ; Kreft, S....
ESMO Open. 9 (2024) 8 - p. 103661 , 2024

Link: https://doi.org/10.1016/..

2

POSA357 Social Media Listening for Melanoma Care Across Eur..:

Chauhan, J ; Aasaithambi, S ; Sagkriotis, A...
Value in Health. 25 (2022) 1 - p. S219 , 2022

Link: https://doi.org/10.1016/..

3

SEOM clinical guideline for the management of cutaneous mel..:

Majem, M. ; Manzano, J. L. ; Marquez-Rodas, I....
Clinical and Translational Oncology. 23 (2021) 5 - p. 948-960 , 2021

Link: https://doi.org/10.1007/..

4

Venous thromboembolism incidence in cancer patients with ge..:

Muñoz, A. J. ; de Toro, M. ; Ortega, L....
Clinical and Translational Oncology. 24 (2021) 1 - p. 154-158 , 2021

Link: https://doi.org/10.1007/..

5

Prognostic significance of sentinel node biopsy status in c..:

Avilés-Izquierdo, J. A. ; Nieto-Benito, L. M. ; Lázaro-Ochaita, P....
Clinical and Translational Oncology. 22 (2020) 9 - p. 1611-1618 , 2020

Link: https://doi.org/10.1007/..

6

Nivolumab (NIVO) vs ipilimumab (IPI) en traitement adjuvant..:

Weber, J. ; Del Vecchio, M. ; Mandalá, M....
Annales de Dermatologie et de Vénéréologie. 147 (2020) 12 - p. A78-A79 , 2020

Link: https://doi.org/10.1016/..

7

A retrospective chart review study describing metastatic me..:

Márquez-Rodas, I. ; Arance, A. ; Berrocal, A....
Clinical and Translational Oncology. 21 (2019) 12 - p. 1754-1762 , 2019

Link: https://doi.org/10.1007/..

8

The RANK–RANKL axis: an opportunity for drug repurposing in..:

Peters, S. ; Clézardin, P. ; Márquez-Rodas, I...
Clinical and Translational Oncology. 21 (2019) 8 - p. 977-991 , 2019

Link: https://doi.org/10.1007/..

9

Nivolumab (NIVO) versus ipilimumab (IPI) dans le traitement..:

Grob, J.-J. ; Weber, J. ; Del Vecchio, M....
Annales de Dermatologie et de Vénéréologie. 146 (2019) 12 - p. A102-A103 , 2019

Link: https://doi.org/10.1016/..

10

Prospective, multicenter study on the economic and clinical..:

Pérez Ramírez, S. ; del Monte-Millán, M. ; López-Tarruella, S....
Clinical and Translational Oncology. 22 (2019) 5 - p. 717-724 , 2019

Link: https://doi.org/10.1007/..

11

Efficacy and safety of immune checkpoint inhibitor immunoth..:

Fox, B. ; de Toro Carmena, M. ; Álvarez Álvarez, R....
Clinical and Translational Oncology. 22 (2019) 4 - p. 555-562 , 2019

Link: https://doi.org/10.1007/..

12

Traitement adjuvant par nivolumab (NIVO) par rapport à l'ip..:

Weber, J.S. ; Mandala, M. ; Del Vecchio, M....
Annales de Dermatologie et de Vénéréologie. 145 (2018) 12 - p. S58 , 2018

Link: https://doi.org/10.1016/..

13

Why do patients with thick melanoma have different outcomes..:

Rodríguez-Lomba, E. ; Marquez-Rodas, I. ; Mercader-Cidoncha, E...
Clinical and Translational Oncology. 19 (2017) 8 - p. 1055-1057 , 2017

Link: https://doi.org/10.1007/..

14

Burden of Healthcare Costs for Merkel Cell Carcinoma Manage..:

Fonfria, H ; Llombart, B ; Arance, A...
Value in Health. 20 (2017) 9 - p. A427 , 2017

Link: https://doi.org/10.1016/..

15

SEOM clinical guideline for the management of malignant mel..:

Berrocal, A. ; Arance, A. ; Castellon, V. E....
Clinical and Translational Oncology. 20 (2017) 1 - p. 69-74 , 2017

Link: https://doi.org/10.1007/..